Drug: CGB-600 gel, experimental drug

Phase 1Small molecule

Drug: CGB-600 gel, experimental drug is one of 39 small molecule programs targeting Vitiligo. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

VitiligoActive, not recruiting

VitiligoPhase 1

Active, not recruiting

Competition

Competitive Landscape

103 competitors in Vitiligo

#DrugCompanyPhaseTrials

Rinvoq

AbbVie

Phase 3

3 2

Opzelura

Pfizer

Phase 3

2 3

Prograf

VVeloxis Pharmaceuticals

Phase 3

8 4

Povorcitinib

Incyte

Phase 3

2 5

Olumiant

Eli Lilly

Phase 2

3 6

Otezla

Amgen

Phase 2

2 7

Saphnelo

AstraZeneca

Phase 2

1 8

Scenesse

CClinuvel Pharmaceuticals Limited

Phase 2

4 9

Enbrel

IImmunex

Phase 2

1 10

Zocor

OOrganon and Co

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Vitiligo

NCT07357870

Clinical

Trials by Indication[1]

Vitiligo1 trial

A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo

Recruiting·CCAGE Bio Inc.·Phase 1·NCT07357870·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Drug: CGB-600 gel, experimental drug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Drug: CGB-600 gel, experimental drug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Drug: CGB-600 gel, experimental drug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CAGE Bio Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCAGE Bio Inc.

Drug: CGB-600 gel, experimental drug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Vitiligo1 trial

References

Drug Info

Quick Facts

Related News